Patent intelligence · US
US 12338437
OPA1 antisense oligomers for treatment of conditions and diseases
OPA1 antisense oligomers for treatment of conditions and diseases
Patent details — US 12338437
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 24, 2025
- Expiration
- Jun 19, 2045
- Applicant
- STOKE THERAPEUTICS, INC.
- Claims
- 20
- CPC classes
- A61K, A61K31/7088, A61K31/7125, A61K45/06
Quick answer
US 12338437 (OPA1 antisense oligomers for treatment of conditions and diseases) is held by STOKE THERAPEUTICS, INC.. Status: granted. Granted Jun 24, 2025. Expires Jun 19, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- STOKE THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/7088, A61K31/7125, A61K45/06, A61K9/0048, A61P
More from STOKE THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12060558
Methods and compositions for treatment of cholesteryl ester storage disease
granted -
US 11873490
Antisense oligomers for treatment of conditions and diseases
granted -
US 11814622
OPA1 antisense oligomers for treatment of conditions and diseases
granted -
US 11096956
Antisense oligomers and uses thereof
granted -
US 11083745
Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
granted -
US 10913947
Antisense oligomers for treatment of conditions and diseases
granted -
US 10683503
Antisense oligomers for treatment of conditions and diseases
granted
Frequently asked questions
What is US patent 12338437?
US 12338437 (OPA1 antisense oligomers for treatment of conditions and diseases) is held by STOKE THERAPEUTICS, INC.. Status: granted. Granted Jun 24, 2025. Expires Jun 19, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12338437?
STOKE THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 12338437 expire?
Our index shows an expiration date of Jun 19, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.